Literature DB >> 6285997

Tricyclic antidepressants induce sphingomyelinase deficiency in fibroblast and neuroblastoma cell cultures.

S Albouz, J J Hauw, Y Berwald-Netter, J M Boutry, R Bourdon, N Baumann.   

Abstract

Tricyclic antidepressants (imipramine and desipramine) gave rise to an important decrease of sphingomyelinase activity in murine neuroblastoma and human fibroblast cell cultures. It occurred within 1 to 2 hours at a final concentration of 1 or 2 X 10(-5) M in cell culture medium. Other lysosomal enzymes such as acid lipase, arylsulfatases A and B and hexosaminidases were not modified. Low level of sphingomyelinase activity may be related to the amphiphilic characteristics of the drugs: iminodibenzyle which has the same tricyclic core but is devoid of the side chain necessary for amphiphilic properties had no effect. As iminodibenzyle has no therapeutic action, amphiphilic may be requisite to antidepressant properties of tricyclic drugs.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6285997

Source DB:  PubMed          Journal:  Biomedicine        ISSN: 0300-0893


  25 in total

1.  A novel mechanism of lysosomal acid sphingomyelinase maturation: requirement for carboxyl-terminal proteolytic processing.

Authors:  Russell W Jenkins; Jolanta Idkowiak-Baldys; Fabio Simbari; Daniel Canals; Patrick Roddy; Clarke D Riner; Christopher J Clarke; Yusuf A Hannun
Journal:  J Biol Chem       Date:  2010-11-22       Impact factor: 5.157

Review 2.  Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.

Authors:  Jeremy Shaw; Pedro Costa-Pinheiro; Logan Patterson; Kelly Drews; Sarah Spiegel; Mark Kester
Journal:  Adv Cancer Res       Date:  2018-06-19       Impact factor: 6.242

Review 3.  Drug targeting of sphingolipid metabolism: sphingomyelinases and ceramidases.

Authors:  Daniel Canals; David M Perry; Russell W Jenkins; Yusuf A Hannun
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

4.  Tricyclic antidepressant amitriptyline inhibits autophagic flux and prevents tube formation in vascular endothelial cells.

Authors:  Yinglu Guan; Xiang Li; Michihisa Umetani; Krishna M Boini; Pin-Lan Li; Yang Zhang
Journal:  Basic Clin Pharmacol Toxicol       Date:  2018-11-15       Impact factor: 4.080

Review 5.  Small Molecule Inhibitors Targeting Biosynthesis of Ceramide, the Central Hub of the Sphingolipid Network.

Authors:  Jan Skácel; Barbara S Slusher; Takashi Tsukamoto
Journal:  J Med Chem       Date:  2021-01-04       Impact factor: 7.446

6.  Roles for tumor necrosis factor receptor p55 and sphingomyelinase in repairing the cutaneous permeability barrier.

Authors:  J M Jensen; S Schütze; M Förl; M Krönke; E Proksch
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

7.  Inhibition of acid sphingomyelinase by imipramine abolishes the synergy between metabolic syndrome and periodontitis on alveolar bone loss.

Authors:  Yanchun Li; Zhongyang Lu; Lixia Zhang; Cameron L Kirkwood; Keith L Kirkwood; Maria F Lopes-Virella; Yan Huang
Journal:  J Periodontal Res       Date:  2021-11-08       Impact factor: 4.419

8.  Molecular analysis of the acid sphingomyelinase deficiency in a family with an intermediate form of Niemann-Pick disease.

Authors:  K Ferlinz; R Hurwitz; M Weiler; K Suzuki; K Sandhoff; M T Vanier
Journal:  Am J Hum Genet       Date:  1995-06       Impact factor: 11.025

9.  Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells.

Authors:  Katrin Anne Becker; Alexander Carpinteiro; Markus Hoffmann; Stefan Pöhlmann; Johannes Kornhuber; Erich Gulbins
Journal:  STAR Protoc       Date:  2021-02-03

10.  Lipid alterations in experimental murine colitis: role of ceramide and imipramine for matrix metalloproteinase-1 expression.

Authors:  Jessica Bauer; Gerhard Liebisch; Claudia Hofmann; Christian Huy; Gerd Schmitz; Florian Obermeier; Jürgen Bock
Journal:  PLoS One       Date:  2009-09-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.